共 5 条
[1]
6518 ORAL Subgroup results from a randomised; double-blind; multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704.[J].W. Eberhardt;M. Reck;J. vonPawel;P. Zatloukal;R. Ramlau;V. Gorbounova;N. Leighl;J. Mezger;N. Moore;C. Manegold.EJC Supplements.2007, 4
[2]
Combined targeted therapies in non-small cell lung cancer: a winner strategy?
[J].
CURRENT OPINION IN ONCOLOGY,
2007, 19 (02)
:98-102
Cascone, Tina
;
Gridelli, Cesare
;
Ciardiello, Fortunato
.
[3]
Cetuximab in advanced non-small cell lung cancer
[J].
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY,
2006, 59 (02)
:139-149
Rossi, Antonio
;
Maione, Paolo
;
Gridelli, Cesare
.
[4]
O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized; placebo-controlled Phase II trial.[J].R. Herbst;B. Johnson;J. Rowbottom;P. Fidias;C. Lu;D. Prager;J. Roubec;E. Csada;I. Dimery;J. Heymach.Lung Cancer.2005,
[5]
O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa?) in patients with NSCLC: Results of a randomized; double-blind Phase II study.[J].R. Natale;D. Bodkin;R. Govindan;B. Sleckman;N. Rizvi;A. Capo;P. Germonpré;I. Dimery;A. Webster;M. Ranson.Lung Cancer.2005,